{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:50:22Z","timestamp":1771501822548,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12032-019-1304-y","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T08:02:41Z","timestamp":1565337761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9761-7431","authenticated-orcid":false,"given":"Nicola","family":"Calvani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Naglieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo Emanuele","family":"Chiuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palma","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"1304_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423\u201336.","journal-title":"Nat Rev Cancer"},{"key":"1304_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/01.cad.0000224454.46824.fc","volume":"17","author":"L Orlando","year":"2006","unstructured":"Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, Goldhirsch A, D\u2019Alessandro C, Cinieri S, Preda L, Colleoni M. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2006;17:961\u20137.","journal-title":"Anticancer Drugs"},{"key":"1304_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1182\/blood-2005-11-4570","volume":"108","author":"P Mancuso","year":"2006","unstructured":"Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood. 2006;108:452\u20139.","journal-title":"Blood"},{"key":"1304_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/030089160909500635","volume":"95","author":"N Calvani","year":"2009","unstructured":"Calvani N, Orlando L, Nacci A, Sponziello F, Cinefra M, Cinieri S. Metronomic chemotherapy against cancer: from paradigm to clinical practice? Tumori. 2009;95:843\u20135.","journal-title":"Tumori"},{"key":"1304_CR5","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.ejca.2013.06.038","volume":"49","author":"K Lien","year":"2013","unstructured":"Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49:3387\u201395.","journal-title":"Eur J Cancer"},{"key":"1304_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/cncr.11713","volume":"98","author":"LM Glode","year":"2003","unstructured":"Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98:1643\u20138.","journal-title":"Cancer"},{"key":"1304_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopha.2004.08.006","volume":"58","author":"A Nicolini","year":"2004","unstructured":"Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, Carpi A, Giardino R. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother. 2004;58:447\u201350.","journal-title":"Biomed Pharmacother"},{"key":"1304_CR8","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.juro.2007.01.143","volume":"177","author":"R Lord","year":"2007","unstructured":"Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177:2136\u201341.","journal-title":"J Urol"},{"key":"1304_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12032-009-9218-8","volume":"27","author":"T Nelius","year":"2010","unstructured":"Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol. 2010;27:363\u20137.","journal-title":"Med Oncol"},{"key":"1304_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ctrv.2010.12.006","volume":"37","author":"T Nelius","year":"2011","unstructured":"Nelius T, Rinard K, Filleur S. Oral\/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev. 2011;37:444\u201355.","journal-title":"Cancer Treat Rev"},{"key":"1304_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.clgc.2014.02.007","volume":"12","author":"M Yashi","year":"2014","unstructured":"Yashi M, Nishihara D, Mizuno T, Yuki H, Masuda A, Kambara T, Betsunoh H, Abe H, Fukabori Y, Muraishi O, Kamai T. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases. Clin Genitourin Cancer. 2014;12:197\u2013203.","journal-title":"Clin Genitourin Cancer"},{"key":"1304_CR12","first-page":"4317","volume":"30","author":"S Ladoire","year":"2010","unstructured":"Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, Mourey E, Michel F, Cormier L, Ghiringhelli F. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res. 2010;30:4317\u201324.","journal-title":"Anticancer Res"},{"key":"1304_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"1304_CR14","first-page":"1878","volume":"60","author":"T Broweder","year":"2000","unstructured":"Broweder T, Butterfield CE, Kraling MT, Marshall B, O\u2019Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878\u201386.","journal-title":"Cancer Res"},{"key":"1304_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10637-013-9974-3","volume":"32","author":"A Chow","year":"2014","unstructured":"Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Preclinical analysisi of resistance and cross-resistance to low-dose metronomic chemotherapy. Invest New Drugs. 2014;32:47\u201359.","journal-title":"Invest New Drugs"},{"key":"1304_CR16","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-08-3317","volume":"15","author":"A Fontana","year":"2009","unstructured":"Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D\u2019Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15:4954\u201362.","journal-title":"Clin Cancer Res"},{"key":"1304_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3727\/096504010X12777678141662","volume":"18","author":"VR Rozados","year":"2010","unstructured":"Rozados VR, Mainetti LE, Rico MJ, Zacarias Fluck MF, Matar P, Scharovsky OG. The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol Res. 2010;18:601\u20135.","journal-title":"Oncol Res"},{"key":"1304_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2006","unstructured":"Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells and restores T and NK effector functions in end stage cancer patient. Cancer Immunol Immunother. 2006;56:641\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"1304_CR19","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/0008-5472.CAN-08-4102","volume":"69","author":"S Wada","year":"2009","unstructured":"Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen H, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity: studies in autochthonous prostate cancer model. Cancer Res. 2009;69:4309\u201318.","journal-title":"Cancer Res"},{"key":"1304_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.eururo.2014.10.004","volume":"67","author":"R Venkitaraman","year":"2015","unstructured":"Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J, Parker C. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol. 2015;67:673\u20139.","journal-title":"Eur Urol"},{"key":"1304_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000048411","volume":"68","author":"M Morioka","year":"2002","unstructured":"Morioka M, Kobayashi T, Furukawa Y, Jo Y, Shinkai M, Matsuki T, Yamamoto T, Tanaka H. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int. 2002;68:10\u20135.","journal-title":"Urol Int"},{"key":"1304_CR22","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-05-2085","volume":"12","author":"A Yano","year":"2006","unstructured":"Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006;12:3003\u20139.","journal-title":"Clin Cancer Res"},{"key":"1304_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/ijc.IJC_346_17","volume":"55","author":"D Dabkara","year":"2018","unstructured":"Dabkara D, Ganguly S, Biswas B, Ghosh J. Metronomic therapy in metastatic castrate-resistant prostate cancer: experience from a tertiary cancer care center. Indian J Cancer. 2018;55:94\u20137.","journal-title":"Indian J Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-019-1304-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T23:23:26Z","timestamp":1596842606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-019-1304-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1304"],"URL":"https:\/\/doi.org\/10.1007\/s12032-019-1304-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"5 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Independent Medical Ethics Committee of ASL Brindisi. Because this was a retrospective study, formal consent was required only for those participants still alive at the time of data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"80"}}